Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …

Background Activating mutations of EZH2, an epigenetic regulator, are present in
approximately 20% of patients with follicular lymphoma. We investigated the activity and …

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-
Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as …

Patients with follicular lymphoma (FL) frequently require multiple treatments during their
disease course; however, survival based on lines of treatment remains poorly described in …

The emergence of cell and gene therapies has dramatically changed the treatment
paradigm in oncology and other therapeutic areas. Kymriah®(tisagenlecleucel), a CD19 …

Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) treatments have been
rapidly evolving for patients treated in later lines of therapy (LoT). Country-specific cancer …

In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19
chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in …

Follicular lymphoma (FL) is the most common indolent B-cell lymphoma and originates from
germinal center B-cells (centrocytes and centroblasts) of the lymphoid follicle …

Background Novel therapies for relapsed or refractory follicular lymphoma are commonly
evaluated in single-arm studies without formal comparison with other treatments or historical …

The SCHOLAR-5 study examines treatment patterns and outcomes of real-world follicular
lymphoma (FL) patients on 3 rd line of treatment (LoT) or higher, for whom existing data are …